Business Overview: Pacira BioSciences, Inc. (NASDAQ: PCRX)

---

Executive Summary

Pacira BioSciences is a commercial-stage biopharmaceutical and medical technology company focused exclusively on non-opioid pain management, built around its flagship product EXPAREL, a long-acting local anesthetic that generated $575.1 million in 2025 — roughly 79% of total company revenue. Pacira has assembled its current portfolio through a string of acquisitions (Pacira Pharmaceuticals, MyoScience, Flexion Therapeutics, and GQ Bio), adding the ZILRETTA osteoarthritis injection, the iovera° cryoanalgesia device, and most recently a gene-therapy pipeline.

The company's commercial strategy rides the "opioid-sparing" policy tailwind, including the federal NOPAIN Act, positioning its products as alternatives to opioid-based postsurgical pain control. However, EXPAREL's dominance creates meaningful concentration risk, and a 2025 patent settlement opens the door to limited generic bupivacaine liposome competition starting in 2030, with unrestricted entry by 2039 — a long runway, but a defined expiration date on Pacira's core moat.

---

1. Core Business Model & How They Work

   Manufacturing (San Diego + Thermo Fisher, Swindon UK)
                        |
                        v
        +---------------------------------+
        |   EXPAREL / ZILRETTA / iovera°   |
        +---------------+-------------------+
                        |
                        v
        +----------------------------------------+
        |  3 Wholesalers (drop-ship program):      |
        |  McKesson (31%), Cardinal Health (26%),  |
        |  AmerisourceBergen (22%) of 2025 revenue  |
        +-----------------+------------------------+
                          |
                          v
        +----------------------------------------+
        |  Direct Sales Force -> Anesthesiologists, |
        |  Surgeons, Pharmacists, Nurses             |
        +-----------------+------------------------+
                          |
                          v
                 Hospitals / Ambulatory
                 Surgery Centers (ASCs)

Pacira manufactures its products in-house (San Diego) and through contract manufacturer Thermo Fisher in the UK, then sells through three wholesalers under a drop-ship model directly to hospitals and surgery centers. A direct sales force targets the clinicians who decide on perioperative pain protocols, reinforced by medical affairs, reimbursement support, and a growing real-world evidence program (the IGOR registry, 3,200+ patients) designed to prove opioid-sparing outcomes to hospital formulary committees.

---

2. Business Segments

Pacira does not break out formal reportable segments; it manages the business as a single non-opioid pain management franchise across three marketed product lines plus pipeline R&D.

                    Pacira BioSciences
                           |
     +----------------+----------------+----------------+
     |                |                |                |
  EXPAREL          ZILRETTA          iovera°          Pipeline
  (bupivacaine     (triamcinolone    (cryoanalgesia   (PCRX-201 gene
  liposome,         ER, OA knee       device)          therapy, HCAd
  79% of revenue)   pain)                               programs)

---

3. Product Portfolio

---

4. Competitive Landscape

Pacira competes against the broader universe of pharmaceutical, medical device, and biotechnology companies addressing postsurgical and chronic pain, though the filing's excerpted Item 1 does not name specific rivals by product. The more durable competitive threat is structural: generic entrants following the 2025 eVenus patent settlement, which permits limited-volume generic bupivacaine liposome starting in early 2030 and unrestricted entry in 2039. In the osteoarthritis space, ZILRETTA's differentiation is its extended-release duration versus standard corticosteroid injections and other OA pain management options.

---

5. Strategic Strengths & Risks

Strengths (Moat Sources)

• EXPAREL is protected by proprietary multivesicular liposome (pMVL) manufacturing technology and multiple expanded-indication approvals (nerve blocks across orthopedics, spine, abdominal, women's health, cardiothoracic, pediatric, and dental procedures), making it difficult to replicate clinically and regulatorily.
• First-mover and sole extended-release status for ZILRETTA in osteoarthritis knee pain, with a Phase 3 shoulder-pain trial extending the franchise.
• A co-promotion agreement with J&J MedTech for ZILRETTA through 2031 extends commercial reach without Pacira bearing full sales-force cost.
• The eVenus patent settlement caps generic bupivacaine liposome competition until 2030 (limited) and 2039 (full), giving Pacira a long, legally defined runway.
• Policy tailwinds from the NOPAIN Act and broader opioid-sparing initiatives support continued hospital adoption of EXPAREL protocols.

Risks

• Extreme product concentration: EXPAREL alone is ~79% of revenue, and three wholesalers (McKesson, Cardinal Health, AmerisourceBergen) represent 79% of total revenue combined.
• The 2025 patent settlement, while favorable in timing, confirms that generic competition is coming within the next decade-plus.
• Heavy reliance on Thermo Fisher as a contract manufacturer for EXPAREL and ZILRETTA.
• Leverage from the Credit Agreement and 2029 convertible notes constrains financial flexibility.
• An unresolved $23.1 million royalty dispute (RDF appeal) plus a $5.2 million interest award remains a contingent liability.
• Pipeline assets (PCRX-201, ZILRETTA shoulder indication) are not yet proven in later-stage trials.

---

6. Financial Overview

---

7. Summary Conclusion

Pacira has built a genuinely defensible, if narrow, franchise around non-opioid pain management, anchored by EXPAREL's proprietary liposome technology, broad label expansions, and favorable policy tailwinds that support continued hospital adoption. The 2025 patent settlement with eVenus is a meaningful de-risking event, converting an open-ended patent-cliff threat into a defined, multi-year runway through 2030 and 2039.

That said, Pacira's near-total dependence on a single product and a concentrated wholesaler base means its long-term value depends heavily on successfully diversifying into ZILRETTA's new indications, iovera°'s expanding use cases, and the still-unproven PCRX-201 gene therapy pipeline before generic competition eventually arrives.